HCM News

The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue, biotech Hutchison China MediTech (HCM). Top-performers are fast-growing tech companies...read more

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

Of the three scheduled healthcare offerings this past week, only two priced. This marks a total of seven IPOs year to date, all from healthcare companies, which have been predominantly development stage biotechs supported by existing backers. While the broader market is stabilizing and returns on recent IPOs are improving, investors are still awaiting the launch of IPOs by...read more

Hutchison China MediTech, a CK Hutchison-backed pharmaceutical with a pipeline of oncology candidates, raised $101 million by offering 7.5 million ADSs at $13.50. In its most recent filing, the company expected to raise $100 million by offering 6.1 million ADSs at $16.33, its last traded price on the AIM market in London. Hutchison China MediTech plans to list on the Nasdaq under...read more